Another tested drug in our screen, Palbociclib, PD0332991, a CDK4/CDK6 inhibitor, that is supposed to target the most frequent deletion in mesothelioma, CDKN2A, showed only minor effects in our cell lines (Table 2). This evidence concerns the gene CDK6 and mesothelioma.